Get the Stockscreener App
1.02
0.97%
-0.01
After Hours:
1.01
-0.01
-0.98%
Renovorx Inc stock is traded at $1.02, with a volume of 109.21K.
It is down -0.97% in the last 24 hours and up +2.00% over the past month.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
See More
Previous Close:
$1.03
Open:
$1.03
24h Volume:
109.21K
Relative Volume:
0.78
Market Cap:
$30.87M
Revenue:
-
Net Income/Loss:
$-9.16M
P/E Ratio:
-1.7895
EPS:
-0.57
Net Cash Flow:
$-8.75M
1W Performance:
+28.95%
1M Performance:
+2.00%
6M Performance:
+2.00%
1Y Performance:
-14.29%
1-Day Range:
$0.98
$1.04
1-Week Range:
$0.751
$1.04
52-Week Range:
$0.75
$1.6899
Renovorx Inc Stock (RNXT) Company Profile
Name
Renovorx Inc
Sector
Industry
Phone
408-800-2649
Address
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
1.02 | 30.87M | 0 | -9.16M | -8.75M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Renovorx Inc Stock (RNXT) Latest News
RenovoRx CMO Makes Bold Stock Purchase! - TipRanks
RenovoRx chief medical officer Agah Ramtin buys $13,500 in common stock - Investing.com Canada
RenovoRx chief medical officer Agah Ramtin buys $13,500 in stock - Investing.com Australia
RenovoRx chief medical officer Agah Ramtin buys $13,500 in stock By Investing.com - Investing.com Canada
RenovoRx chief medical officer Agah Ramtin buys $13,500 in common stock By Investing.com - Investing.com South Africa
RenovoRx ramps up production of FDA-cleared RenovoCath By Investing.com - Investing.com India
New Jersey Patients Receiving First-of-Its-Kind Catheter Based Pancreatic Cancer Treatment | Newswise - Newswise
RenovoRx CEO Shaun Bagai acquires $6,821 in common stock - Investing.com Australia
RenovoRx CEO Shaun Bagai acquires $6,821 in common stock By Investing.com - Investing.com Canada
RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community - BioSpace
RenovoRx ramps up production of FDA-cleared RenovoCath - Investing.com
Renovorx Increases U.S. Production Of Renovocath Devices To Meet Growing Demand From Oncology Community - marketscreener.com
Medical Device Maker RenovoRx Eyes $400M Market With Surging RenovoCath Demand - Stock Titan
RenovoRx CMO Makes Bold Stock Purchase - TipRanks
RenovoRx chief medical officer Agah Ramtin buys $16,000 in stock By Investing.com - Investing.com India
RenovoRx chief medical officer Agah Ramtin buys $16,000 in stock - Investing.com
Top Executives Make Bold Moves with RenovoRx Stock Purchases! - TipRanks
RenovoRx VP controller Ronald Kocak acquires over $10,000 in stock By Investing.com - Investing.com Canada
RenovoRx VP controller Ronald Kocak acquires over $10,000 in stock - Investing.com Australia
RenovoRx Executives Increase Their Holdings - TradingView
RenovoRx CMO Agah Ramtin purchases $24,399 in common stock By Investing.com - Investing.com India
RenovoRx CMO Agah Ramtin purchases $24,399 in common stock - Investing.com
RenovoRx CEO Shaun Bagai acquires $8,300 in common stock By Investing.com - Investing.com Canada
RenovoRx CEO Shaun Bagai acquires $8,300 in common stock - Investing.com
RenovoRx CMO Makes a Bold Move with Major Stock Purchase - TipRanks
Renovorx director Marton Laurence buys $10,218 in common stock By Investing.com - Investing.com India
RenovoRx Executives Increase Stake in Company - TradingView
Renovorx director Marton Laurence buys $10,218 in common stock - Investing.com
Renovorx chief medical officer Agah Ramtin buys $21,840 in shares - Investing.com Australia
Renovorx chief medical officer Agah Ramtin buys $21,840 in shares By Investing.com - Investing.com Canada
RenovoRx CEO Shaun Bagai purchases $8,300 in company stock By Investing.com - Investing.com Canada
RenovoRx CEO Shaun Bagai purchases $8,300 in company stock - Investing.com
RenovoRx stock hits 52-week low at $0.77 amid market challenges - Investing.com Australia
RenovoRx stock hits 52-week low at $0.77 amid market challenges By Investing.com - Investing.com South Africa
HC Wainwright Reaffirms “Buy” Rating for RenovoRx (NASDAQ:RNXT) - Defense World
H.C. Wainwright maintains Buy rating on RenovoRx stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy rating on RenovoRx stock - Investing.com Australia
RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th - Business Wire
RenovoRx: Promising Phase 3 Study and Revenue Growth Drive Buy Rating - TipRanks
RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial - ADVFN
RenovoRx Inc reports results for the quarter ended December 31Earnings Summary - TradingView
RenovoRx projects growth with new orders and clinical trial - Investing.com
RenovoRx projects growth with new orders and clinical trial By Investing.com - Investing.com South Africa
Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial - Business Wire
RenovoRx, Inc. SEC 10-K Report - TradingView
RenovoRx Hits Major Milestone: First Revenue from Cancer Device as Phase 3 Trial Nears Key Analysis - Stock Titan
RenovoRx Delays Yearly Report Filing - TipRanks
Renovorx Inc Stock (RNXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Renovorx Inc Stock (RNXT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bagai Shaun | Chief Executive Officer |
Apr 15 '25 |
Buy |
0.91 |
7,500 |
6,821 |
320,040 |
| Agah Ramtin | Chief Medical Officer |
Apr 11 '25 |
Buy |
0.80 |
20,000 |
16,000 |
1,098,460 |
| Kocak Ron | VP Controller and PAO |
Apr 10 '25 |
Buy |
0.79 |
6,500 |
5,135 |
12,595 |
| Kocak Ron | VP Controller and PAO |
Apr 09 '25 |
Buy |
0.80 |
6,000 |
4,800 |
6,095 |
| Kocak Ron | VP Controller and PAO |
Apr 08 '25 |
Buy |
0.80 |
95 |
76 |
95 |
| Agah Ramtin | Chief Medical Officer |
Apr 09 '25 |
Buy |
0.81 |
30,000 |
24,399 |
1,078,460 |
| Bagai Shaun | Chief Executive Officer |
Apr 09 '25 |
Buy |
0.83 |
10,000 |
8,300 |
312,540 |
| Marton Laurence | Director |
Apr 08 '25 |
Buy |
0.85 |
12,050 |
10,218 |
45,684 |
| Agah Ramtin | Chief Medical Officer |
Apr 08 '25 |
Buy |
0.84 |
26,000 |
21,840 |
1,048,460 |
| Bagai Shaun | Chief Executive Officer |
Apr 07 '25 |
Buy |
0.83 |
10,000 |
8,300 |
302,540 |
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):